CytoDyn Inc. (ticker: CYDY) is an OTC-listed pharma company. DredgeCap's structured extraction of CYDY's SEC filings surfaces 5 active risk signals, including 3 late-filing signals, 1 auditor-change signal, and 1 delisting/deregistration signal. CYDY reported $0 in revenue and -$32.84M for the period ending 2023-05-31, with operating cash flow of -$12.32M. Cash and equivalents stood at $15.65M (down 4.5% year-over-year). Total assets of $18.50M are exceeded by total liabilities of $122.78M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
CYDY Legal Proceedings
DredgeCap has not located any disclosed legal proceedings for CytoDyn Inc. (CYDY) in the SEC filings currently cached or in the federal-court records searched. 0 periodic filings reviewed, 0 with specific disclosure content. The absence of records here does not certify that the company is free of litigation — coverage reflects only what DredgeCap has cached.